Skip to main content

Table 1 Genomic Alterations Identified by Hybrid Capture

From: Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Gene Alteration Loss or Gain of Function Predictor of Response to Pembrolizumab
CD274 (PD-L1) amplification Gain Yes
STK11 S216F and LOH Loss Negative predictor
MYC amplification Gain No
APC E2516 Loss No
RB1 Loss No
TP 53 R158 L Loss No
Back to article page